Child & Adolescent Psychopharmacology 2019 (Mar 15 - 17, 2019)
Child & Adolescent Psychopharmacology 2019 is organized by Massachusetts General Hospital (MGH) Psychiatry Academy and will be held from Mar 15 - 17, 2019 at Aulani, A Disney Resort & Spa, Kapolei, Hawaii, United States of America.
The target audience for this medical event is Psychiatrists, Primary care and family practice physicians, Pediatricians, Psychologists, Nursing professionals, Social workers, Residents, Other mental health, primary care and pediatric clinicians. This CME Conference has been approved for a maximum of 20.75 AMA PRA Category 1 Credits.
This renowned conference provides a complete update on research, assessment, and treatment of mental health conditions in children and adolescents. It is ideal if you work in mental health, primary care, nursing, psychology, school health, and more.
• Hear guidance on translating new research into clinical practice for substance use disorders, mood disorders, OCD, schizophrenia, anxiety disorders, and more.
• Find sessions on pharmacologic treatments, psychological interventions, naturopathic treatments, suicide risk and prevention, implications of genetics, and much more.
• Ask questions and discuss cases during Curbside Consultation hours with experts on specific topics.
• Find insights that enhance your clinical work in psychiatric practices, community clinics, hospitals, school-based settings, primary care offices, university clinics, and psychology practices.
• Neurobiology, genetics and neuroimaging
• Treatment of pediatric ADHD
• CBT & psychosocial treatments
• ADHD and learning disabilities
• Treatment of comorbidities
• Legal issues in treating ADHD
Conference Objectives are:
• Recognize the presentation, diagnosis, and current treatment options available for attention deficit and hyperactivity in childhood and adolescence.
• Identify the presentation, diagnosis, and current treatment options available for behavioral problems and pervasive developmental disorders.
• Discuss the presentation, diagnosis, and current treatment options available for depression, psychosis, manic depression, and anxiety.
• Compare and contrast basic neuropharmacology, neuropsychologic testing data, psychopharmacologic properties of compounds, and the implications of psychiatric genetics for guiding day-to-day pediatric psychopharmacology treatment.
• Recognize the risk management issues associated with adolescent substance use disorder and smoking, ethical and safe use of psychotropics, suicide risk and prevention, cardiovascular side effects and medical liability of stimulants, and liability prevention in psychopharmacology.
• Review the comorbidity of ADHD with posttraumatic stress disorder and traumatic brain injury.
• Explore emotional dysregulation, executive function, and learning disorders in the context of ADHD.
Additional details will be posted as soon as they are available.
|Contact No.||:||(866) 644-7792|
|Registration Type||Due Date||Price|
|MDs/Doctoral-Level Professionals - Super Early fee||16 Nov,2018||USD 645.00|
|Other Professionals or Trainees - Super Early fee||16 Nov,2018||USD 545.00|